References
1.
Panju A, Farkouh ME, Sackett DL. Outcome of patients
discharged from a coronary car unit with a diagnosis of "chest pain not
yet diagnosed.". CMAJ. 1996; 155:541-547.
2. Zaacks SM, Liebson PR, Calvin JE. Parrillo
JE, KleinLW. Unstable angina and non-Q wave myocardial infarction: Does
the clinical diagnosis have therapeutic implications? JACC. 1999; 33:107-18.
3. Katz DA, Griffith JL, Bershansky JR, Selker
HP. The use of empiric clinical data in the evaluation of practice guidelines
for unstable angina. JAMA. 1996;276:1568-1574.
4. Lopez de Sa E, Lopez-Sendon J, Bethencourt A, Bosch X. Prognostic
value of EKG changes during chest pain in patients with unstable angina.
Results of the proyecto de estudia del pronostico de la angina (PEPA).
J Am Coll Cardiol.1998; 31(suppl A):79A.
5. Kaski JC, Chester MR, Chen L et al. Rapid
angiographic progression of coronary artery disease in patients with angina
pectoris: The role of complex stenosis morphology. Circulation 1995 ;92
:2058-2065
6. Ottanl F, Galvani M Ferrini D et al. Direct
comparison of early elevation of cardiac troponin t and I in patients
with clinical unstable angina. Am Heart J. 1999;137:284-291.
7. ISIS-2 Collaborative Group. Randomized trail
of intravenous streptokinase, oral aspirin, both or neither among 17,187
cases of suspected myocardial infarction: ISIS-2. Lancet. 1988;2:349-360.
8. Mark DB, Cowper PA, Berkowitz SD, et al.
Economic assessment of low-molecular-weight heparin (enoxaparin) versus
unfractionated heparin in acute coronary syndrome patients results from
ESSENCE randomized trial. Efficacy and safety of subcutaneous Enoxaparin
in non-Q wave coronary events. Circ. 1998;97:1702-1707
9. Eikelboom JW, Anand SS, Sonia SS, et al.
Unfractionated heparin and low-molecular-weight heparin in acute coronary
syndrome without ST elevation: a meta-analysis. Lancet. 2000;355 :1936-1942.
10. TIMI IIIB Investigators. Effect of tissue
plasminogen activator and a comparison of early invasive and conservative
strategies in unstable angina and non-Q wave myocardial infarction.Circulation.1994;89:1545-1556.
11. PRISM-PLUS investigators. Inhibition of
the platelet Glycoprotein IIb/IIIa receptor with tirofiban in unstable
angina and non-Q wave Myocardial infarction. N Eng J Med. 1998; 338: 1488-1497.
12. Sabatine MS, Jang I. The use of glycoprotein
IIb/IIIa inhibitors in patients with coronary artery disease. Am J Med
2000: 109(3) 224-237.
13. The CAPTURE investigators. Randomized placebo-controlled
trial of abciximab before and during coronary intervention in refractory
unstable angina: the CAPTURE study. Lancet. 1997:349:1429-1435.
14. The PRISM PLUS Investigators. Inhibition
of the platelet glycoprotein IIb/IIIa receptor with tirofibin in unstable
angina and non-Q wave Myocardial infarction. N Eng J Med. 1998;338:1488-1497.
15. The GUSTO Investigators. An international
randomization trial comparing four thrombolytic strategies for acute myocardial
infarction. N Engl J Med. 1993;329:673-82.
16. The Global Use of Strategies to Open Occluded
Coronary Arteries (GUSTO III) Investigators. A comparison of reteplase
with alteplase for acute myocardial infarction. N Engl J Med. 1997;337:1118-1123.
17. The GUSTO V investigators. Reperfusion
therapy for acute myocardial infarction with fibrinolytic therapy or combination
reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition:
the GUSTO V randomized trial. Lancet. 2001;357:1905-1914.
18. The ASSENT 3 Investigators. Efficiency
and safety of tenecteplase in combination with enoxaparin, abciximab,
or unfractionated heparin: ASSENT-3 randomized trial in acute myocardial
infarction. Lancet. 2001;358:605-613.
19. Ross AM, Molhoek P, Lundergan C, et al.
Randomized comparison of enoxaparin, a low molecular weight heparin, with
unfractionated heparin adjunctive to recombinant tissue plasminogen activator
thrombolysis and aspirin: second trial or Heparin and Aspirin Reperfusion
Therapy (HART II). Circ. 2001; 104: 648-652.